Latest appendicitis Stories
A new study suggests that surgery for appendicitis that uses a pinhole incision through the navel may be a feasible alternative to traditional appendectomies. Published early online in the British Journal of Surgery, the findings indicate that larger studies to test the potential of the procedure are warranted. An experimental, minimally invasive, and scarless surgical procedure for appendicitis called transgastric appendicectomy avoids the use of external incisions and causes less pain...
Conference Call and Webcast scheduled for March 26, 2013, 4:30 p.m. ET CASTLE ROCK, Colo., March 19, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its rapid, protein biomarker-based appendicitis test, APPY1, today announced it will provide a fourth quarter business update on Tuesday, March 26, 2013, at 4:30 p.m. ET. The conference call will be hosted by Steve Lundy, Chief Executive Officer;...
Market Development Efforts to be Initiated in Italy and Turkey CASTLE ROCK, Colo., March 18, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE-Marked blood-based appendicitis test, APPY1, today announced it has executed two additional commercial development agreements as part of the initial phase of the European launch. MOSS S.p.A. of Italy and SAVAS Medikal Inc. of Turkey have committed to...
CASTLE ROCK, Colo., March 11, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced that it will present at the 25th Annual ROTH Conference, to be held March 17-20, 2013, at the Ritz-Carlton Laguna Niguel in Dana Point, CA. Steve Lundy, President and CEO of Venaxis, will provide an overview of the Company's business during his live...
CASTLE ROCK, Colo., Feb. 4, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced that Steve Lundy, President and Chief Executive Officer, will present at RetailInvestorConferences.com. DATE: February 7, 2013 TIME: 10:00 AM EST LINK: www.retailinvestorconferences.com > Click red "register /watch event now" button...
CASTLE ROCK, Colo., Jan. 23, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced that it will present at the 2013 BIO CEO and Investor Conference, to be held February 11-12, 2013, at the Waldorf Astoria Hotel in New York. The Conference is organized by the Biotechnology Industry Organization and is the largest investor conference focused on...
CASTLE ROCK, Colo., Jan. 15, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced that it has begun enrolling patients into its pivotal clinical study in the United States. Based on current enrollment expectations, the Company anticipates completing the study in six to eight months and filing with the FDA for regulatory clearance of APPY1 in...
CASTLE ROCK, Colo., Jan. 7, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company, today announced it has fulfilled the requirements for CE Marking in Europe for APPY1, the Company's blood-based appendicitis test. Initial commercialization in Europe is planned to commence in the first quarter 2013 in key territories, including the UK, Italy, France, Germany and Benelux countries. The Company expects to announce agreements with top EU distributors beginning...
CASTLE ROCK, Colo., Jan. 2, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced that it will present at Biotech Showcase 2013, held January 7-9, 2013, at the Parc 55 Wyndham Union Square Hotel in San Francisco, California. Steve Lundy, President and CEO of Venaxis, will provide an overview of the Company's business during his live...
Study authors explain that findings published in Journal of American College of Surgeons point to the need for further research on why these racial disparities exist and what preventive interventions can be developed When researchers from UCLA Medical Center investigated the link between racial disparities and appendicitis outcomes in children, they found that the type of hospital in which black, Hispanic and other minority patients receive care—community, children's or county—affects...
Latest appendicitis Reference Libraries
A laparoscopy is an invasive surgical procedure used in abdominal area but is much less invasive than the preceding methods. Small incisions are made in the abdomen or pelvic area in which the camera and tools are introduced to perform the surgery or inspect the area. The method before the laparoscopy involved cutting open the area completely with longer healing time and more complications. Although in the pediatric populations, abscesses have a tendency to form around the incision sites....
